Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus LAMICTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus LAMICTAL.
FELBATOL vs LAMICTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant